Literature DB >> 10192507

Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes.

J Chapman1, M Cohen-Armon, Y Shoenfeld, A D Korczyn.   

Abstract

Antiphospholipid antibodies (aPL) are associated with neurological diseases such as stroke, migraine, epilepsy and dementia and are thus associated with both vascular and non-vascular neurological disease. We have therefore examined the possibility that these antibodies interact directly with neuronal tissue by studying the electrophysiological effects of aPL on a brain synaptosoneurosome preparation. IgG from patients with high levels of aPL and neurological involvement was purified by protein-G affinity chromatography as was control IgG pooled from ten sera with low levels of aPL. Synaptoneurosomes were purified from perfused rat brain stem. IgG from the patient with the highest level of aPL at a concentration equivalent to 1:5 serum dilution caused significant depolarization of the synaptoneurosomes as determined by accumulation of the lipophylic cation [3H]-tetraphenylphosphonium. IgG from this patient as well as IgG from two elderly patients with high levels of aPL were subsequently shown to permeabilize the synaptosomes to labeled nicotinamide adenine dinucleotide (NAD) and pertussis toxin-ADP-ribose transferase (PTX-A protein) as assayed by labeled ADP-ribosylation of G-proteins in the membranes. No such effects were seen with the control IgG. aPL may thus have the potential to disrupt neuronal function by direct action on nerve terminals. These results may explain some of the non-thromboembolic CNS manifestations of the antiphospholipid syndrome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10192507     DOI: 10.1191/096120399678847524

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  42 in total

Review 1.  Neuropsychiatric lupus.

Authors:  J G Hanly
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

Review 2.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 3.  Antiphospholipid syndrome and cognition.

Authors:  Bernardo Liberato; Roger A Levy
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

4.  Acute transverse myelitis in psoriatic arthritis.

Authors:  Judith J G Rath; H Karel Ronday; Paul Willem Wirtz
Journal:  J Neurol       Date:  2009-12-10       Impact factor: 4.849

Review 5.  Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons.

Authors:  Eyal Muscal; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

6.  Chorea in primary antiphospholipid syndrome is associated with rheumatic fever.

Authors:  Simone Appenzeller; Steeven Yeh; Marcelo Maruyama; Solange Murta Barros; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2011-09-01       Impact factor: 2.631

7.  Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis.

Authors:  D Paran; J Chapman; A D Korczyn; O Elkayam; O Hilkevich; G B Groozman; D Levartovsky; I Litinsky; D Caspi; Y Segev; V E Drory
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

8.  Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV).

Authors:  R M Andrade; G S Alarcón; L A González; M Fernández; M Apte; L M Vilá; G McGwin; J D Reveille
Journal:  Ann Rheum Dis       Date:  2007-09-17       Impact factor: 19.103

Review 9.  Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome.

Authors:  José Fidel Baizabal-Carvallo; Cecilia Bonnet; Joseph Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2013-04-13       Impact factor: 3.575

10.  Cross-reactivity between annexin A2 and Beta-2-glycoprotein I in animal models of antiphospholipid syndrome.

Authors:  R Weiss; A Bitton; L Nahary; M T Arango; I Benhar; M Blank; Y Shoenfeld; J Chapman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.